Skip to main content
The William Harvey Research Institute - Faculty of Medicine and Dentistry

Professor Sir Mark Caulfield

Mark

Vice Principal for Health for Queen Mary’s Faculty of Medicine and Dentistry

Centre: Clinical Pharmacology and Precision Medicine

Email: m.j.caulfield@qmul.ac.uk
Telephone: +44(0) 20 7882 3403

Profile

ORCID iD: 0000-0001-9295-3594

Professor Sir Mark Caulfield is Professor of Clinical Pharmacology at Queen Mary University of London and the Vice Principal for Health for Queen Mary’s Faculty of Medicine and Dentistry.

Professor Caulfield graduated in Medicine in 1984 from the London Hospital Medical College and trained in Clinical Pharmacology at St Bartholomew’s Hospital, he developed a research programme in molecular genetics of hypertension and translational clinical research.

At Queen Mary University of London Professor Caulfield has made contributions to the discovery of genes related to blood pressure, cardiovascular health, cancer and rare diseases. His research has changed national and international guidance for high blood pressure.

He has won the Lily Prize of the British Pharmacology Society, the Bjorn Folkow Award of the European Society of Hypertension 2016 and the Franz Volhard Award of the International Society of Hypertension in 2018.

Professor Caulfield was appointed Chief Scientist for Genomics England in 2013, charged with delivery of the 100,000 Genomes Project on whole genome sequencing in rare disease, cancer and infection. He was instrumental in delivering the 100,000 Genomes Project which has delivered life-changing results for many patients. He worked with NHS England to co-create the National Genomic Test Directory, which offers equitable access for 56 million people to appropriate genomic tests.  Professor Caulfield was awarded a knighthood in 2019 for his leadership of the 100,000 Genomes Project.

He is a member of the Barts Health NHS Trust Board, the Barking, Havering and Redbridge University Hospitals NHS Trust, the MedCity Board and is the President Elect of the British Pharmacological Society

Research

Group members

NIHR Barts Biomedical Research Centre Director’s Office
Clare Birch (Executive Assistant); John Whiteley (Chief Operating Officer for the NIHR Barts Biomedical Research Centre).

Cardiovascular Genetics and Genomics
Dr Helen Warren (Lecturer); Dr Claudia Cabrera (Lecturer); Prof Mike Barnes (Director of Bioinformatics); Dr Emma Forton Macgavern (Academic Clinical Fellow);
Dr Arianna Tucci (MRC Clinician Scientist); Dr Kristina Ibanez Garikano (Lecturer).

William Harvey Clinical Research Centre
Dr David Collier (Clinical Director); Dr Manish Saxena (Clinical Fellow); Dr Julian Shiel (Clinical Fellow); Marion Benford (Quality Assurance); Mike Taylor (Recruitment); Patrizia Ebano; Ania Michalska (Research Sisters).

Summary

Cardiovascular Genomics
My leadership of international research collaborations of 350 researchers from 24 countries has discovered over 1200 gene regions influencing blood pressure and generated a polygenic risk scores for hypertension published in Nature and Nature Genetics and recognised by two of the most prestigious prizes in cardiovascular research.

Genomics England
In 2013 I was asked to become Chief Scientist for Genomics England (GEL) to lead scientific strategy and delivery of the 100,000 Genomes Project. I drew on my extensive experience of collaborative working as a researcher, as an NIHR Biomedical Research Centre Director and Senior Investigator to create the vital coalition of 5000 healthcare professionals, 3400 researchers and 97,000 participants, in partnership with the NHS, to deliver the 100,000 Genomes Project on target creating the platform for a new Genomic Medicine Service (GMS).

Cardiovascular Clinical Research
I have undertaken internationally leading translational and outcomes trials research e.g. the ASCOT trial, which changed international and NICE guidance for lipid lowering and hypertension and the PATHWAY Study which changed European Guidance. From this Barts and The London now have a major clinical trials programme and a partnership with IQVIA where we coordinate and enhance clinical research across UCLP Partners Academic Health Sciences Centre.

Publications

  • Collier D, Taylor M, Godec T et al. (2024). Do more with less? Impact of personalized very low doses of amlodipine in the PERSONAL-CovidBP trial. nameOfConference


    QMRO: qmroHref
  • Magavern EF, Deshmukh H, Asselin G et al. (2024). Pharmacogenomics of CRP response to statins: a GIST consortium study. nameOfConference


    QMRO: qmroHref
  • Hepburn D, Hitchings AW, Wilson K et al. (2024). Importance of the UK Prescribing Safety Assessment as a component of undergraduate medical assessment. nameOfConference


    QMRO: qmroHref
  • Magavern EF, McDermott JH, Caulfield MJ et al. (2024). CYP2C19 genetic testing for Mavacamten and ischaemic stroke treatment: What does the result mean for cardiovascular prescribers in the UK and Europe?. nameOfConference


    QMRO: qmroHref
  • Shi S, Rubinacci S, Hu S et al. (2024). A Genomics England haplotype reference panel and imputation of UK Biobank. nameOfConference


    QMRO: qmroHref
  • Magavern EF, Kapil V, Saxena M et al. (2024). Use of Genomics to Develop Novel Therapeutics and Personalize Hypertension Therapy. nameOfConference


  • Caulfield M (2024). Foreword. nameOfConference


    QMRO: qmroHref
  • Magavern EF, Jacobs B, Warren H et al. (2023). CYP2C19 genotype prevalence and association with recurrent myocardial infarction in British-South Asians treated with clopidogrel. nameOfConference


    QMRO: qmroHref
  • Magavern EF, Van Heel DA, Smedley D et al. (2023). SLCO1B1*5 is protective against non-senile cataracts in cohort prescribed statins: analysis in a British-South Asian cohort. nameOfConference


    QMRO: qmroHref
  • Magavern EF, Hitchings A, Bollington L et al. (2024). UK Prescribing Safety Assessment (PSA): The development, implementation and outcomes of a national online prescribing assessment. nameOfConference


View Profile Publication Page

News

 

Back to top